Single-Dose 20-Valent Pneumococcal Conjugate Vaccine Safe, Immunogenic In Children, Study Finds

Infectious Disease Advisor (5/22, Barowski) reports, “The 20-valent pneumococcal conjugate vaccine is safe and elicits robust immune responses to all 20 serotypes in children aged 15 months to younger than 18 years, according to study results published in The Pediatric Infectious Disease Journal.” In the study, “in patients younger than 5 years, the geometric mean fold rise (GMFR) in IgG from baseline to 1 month after vaccination ranged from 27.9 to 1847.7 (7 additional serotypes) and 2.9 to 44.9 (13-valent pneumococcal conjugate vaccine serotypes).”